FA
TXMD icon

Fedenia Advisers’s TherapeuticsMD TXMD Stock Holding History

Fedenia Advisers’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88 Buy
+40
New +$83 ﹤0.01% 459
2025
Q1 		– Sell
-40
Closed -$34 – 408
2024
Q4 		$34 Buy
+40
New +$56 ﹤0.01% 456

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Fedenia Advisers's TXMD Position: Q2 2026 in Review

Fedenia Advisers opened a new position in TherapeuticsMD (TXMD) in Q2 2026: 40 shares worth $88. The stake represents ﹤0.01% of the portfolio and ranks #459 among its holdings. This is a return to the name: Fedenia Advisers previously reported a position in TXMD as recently as Q4 2024.

Fedenia Advisers first reported a position in TXMD in Q4 2024 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • Fedenia Advisers held 40 shares of TherapeuticsMD worth $88 as of Q2 2026.
  • TherapeuticsMD was a new Fedenia Advisers position in Q2 2026.
  • TherapeuticsMD made up ﹤0.01% of Fedenia Advisers's portfolio in Q2 2026, its #459 holding.
  • Fedenia Advisers first reported a position in TherapeuticsMD in Q4 2024 and has held it in 2 quarters since.
  • 45 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on Fedenia Advisers's 13F filing for Q2 2026, filed 22 Jul 2026.